Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study

Author： Moro-Sibilot Denis   Vergnenegre Alain   Smit Egbert F.   Toy Elisabeth   Parente Barbara   Schmitz Stephan   Kraaij Kees   Visseren-Grul Carla   Soldatenkova Victoria   Arellano Jorge   Leteneux Claudia  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.11, 2010-11, pp. : 2661-2672

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite

A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 31, Iss. 4, 2008-03 ,pp. : 185-189

Karger

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC

By  

Reviews on Recent Clinical Trials, Vol. 6, Iss. 1, 2011-01 ,pp. : 44-51

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite